We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. Akoya offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers the PhenoCycler™ and PhenoImager™ platforms to serve the diverse needs of researchers across discovery, translational and clinical research.
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services.
Our industry-leading RNAscopeTM ISH products provide powerful spatial genomic and spatial transcriptomic tools for sensitive detection, characterization, and detailed localization of all types of cellular nucleic acids at single-molecule resolution, within an intact tissue.
Novogene utilises scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realise their research goals in the rapidly evolving world of genomics. With over 2,000 employees, multiple locations around the world, 37 NGS related patents, and over 670 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. In this conference, we will exhibit the latest genome sequencing solutions.
RAN Biotechnologies provides consumables, kits and devices for next generation science in general and for high-throughput multiomics in particular.
Examples of RAN biotech’s products:
Micro and Nanomaterials for Capturing and Concentrating Microbes.
For inquiries, contact us at Em: [email protected]; Ph: 001 (833) 726-2661.
LevitasBio has developed the LeviCell platform, a powerful new solution for cell processing and characterization. Unlike other single-cell separation methods, levitation does not require dyes, antibodies, or labels, and the cells are not perturbed in any fashion. The cells are visualized in real-time, enabling complete analysis of the sample. The ability to enrich live cells with high recovery is particularly significant for applications such as single-cell sequencing, cell line development, iPSC workflows, and CRISPR workflows.
The patent-pending Singulator™ 100 and 200 systems from S2 Genomics automate dissociation of solid tissue samples as small as 1 mg into suspensions of viable cells or nuclei. Designed for ease of use and protocol optimization, the systems produce high quality suspensions from a wide variety of tissues and organisms. Core labs, individual researchers, and translational reseach groups in pharma and biotech have widely adopted the Singulator as the tissue dissociation platform of choice.
Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company's proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through an oversubscribed early access program. Resolve Biosciences is privately held and headquartered in Monheim, Germany. For additional information, visit www.resolvebiosciences.com